The FASEB Journal, Vol 4, 2737-2744, Copyright © 1990 by The Federation of American Societies for Experimental Biology

REVIEWS

Dopamine receptors and transporters in Parkinson's disease and schizophrenia

P Seeman and HB Niznik
Department of Pharmacology, University of Toronto, Ontario, Canada.

The loss of midbrain dopamine in Parkinson's disease is accompanied by a matching loss in the dopamine transporter and a rise in the D1 and D2 receptor densities. This is found in the brain putamen and caudate tissues from unmedicated patients, and may account for the good early clinical response to L-dopa. Long-term L-dopa treatment reverts the receptor densities toward normal levels. Positron emission tomography (PET) data and in vitro data generally concur. In schizophrenia the density of the dopamine transporter as well as that of the D1 dopamine receptor is normal. The D2 receptor density, however, is consistently elevated in postmortem brain putamen and caudate nucleus, even in tissues from neuroleptic-free or drug-naive patients. Three sets of PET and single photon emission computed tomography (SPECT) data support the postmortem findings. Early evidence indicating abnormal D2 structure as well as a reduced link between D1 and D2 warrant a detailed study of the genes for these two receptors in schizophrenia.

This article has been cited by other articles:

				T. W. Weickert, A. Terrazas, L. B. Bigelow, J. D. Malley, T. Hyde, M. F. Egan, D. R. Weinberger, and T. E. Goldberg Habit and Skill Learning in Schizophrenia: Evidence of Normal Striatal Processing With Abnormal Cortical Input Learn. Mem., November 1, 2002; 9(6): 430 - 442. [Abstract] [Full Text] [PDF]

				S. J. Cragg, C. J. Hille, and S. A. Greenfield Functional Domains in Dorsal Striatum of the Nonhuman Primate Are Defined by the Dynamic Behavior of Dopamine J. Neurosci., July 1, 2002; 22(13): 5705 - 5712. [Abstract] [Full Text] [PDF]

				T. Ilani, D. Ben-Shachar, R. D. Strous, M. Mazor, A. Sheinkman, M. Kotler, and S. Fuchs A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes PNAS, January 5, 2001; (2001) 21535398. [Abstract] [Full Text]

				F. M. Benes, J. B. Taylor, and M. C. Cunningham Convergence and Plasticity of Monoaminergic Systems in the Medial Prefrontal Cortex during the Postnatal Period: Implications for the Development of Psychopathology Cereb Cortex, October 1, 2000; 10(10): 1014 - 1027. [Abstract] [Full Text] [PDF]

				A. E. Busch, U. Karbach, D. Miska, V. Gorboulev, A. Akhoundova, C. Volk, P. Arndt, J. C. Ulzheimer, M. S. Sonders, C. Baumann, et al. Human Neurons Express the Polyspecific Cation Transporter hOCT2, Which Translocates Monoamine Neurotransmitters, Amantadine, and Memantine Mol. Pharmacol., August 1, 1998; 54(2): 342 - 352. [Abstract] [Full Text]

				M. R. Bennett Monoaminergic synapses and schizophrenia: 45 years of neuroleptics J Psychopharmacol, January 1, 1998; 12(3): 289 - 304. [Abstract] [PDF]

				G. Flores, G. K. Wood, J.-J. Liang, R. Quirion, and L. K. Srivastava Enhanced Amphetamine Sensitivity and Increased Expression of Dopamine D2 Receptors in Postpubertal Rats after Neonatal Excitotoxic Lesions of the Medial Prefrontal Cortex J. Neurosci., November 15, 1996; 16(22): 7366 - 7375. [Abstract] [Full Text] [PDF]

				J. M. Kane Schizophrenia N. Engl. J. Med., January 4, 1996; 334(1): 34 - 42. [Full Text] [PDF]

				T. Ilani, D. Ben-Shachar, R. D. Strous, M. Mazor, A. Sheinkman, M. Kotler, and S. Fuchs A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes PNAS, January 16, 2001; 98(2): 625 - 628. [Abstract] [Full Text] [PDF]